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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 2-2.5 hours of work and is not intended to be a comprehensive 
summary of evidence. 
Foundation for Innovative New Diagnostics (FIND): COVID-19 diagnostic evaluation 
update 
FIND | 2 April 2020 | News 
https://www.finddx.org/covid-19/sarscov2-eval-immuno/ 
FIND are independently evaluating immunoassays (manual ELISA, machine-based or lateral flow) 
rapid tests specific for SARS-CoV-2. Twenty-six antibody-detection rapid diagnostic tests and five 
antigen-detection rapid diagnostic tests have been selected - based on regulatory status and time 
to market, manufacturing and distribution capacity of the supplier and clinical and analytical 
performance - for the first round of performance evaluation. Additional tests will be reviewed on a 
rolling basis. Results will be made available. 
Using observational data to quantify bias of traveller-derived COVID-19 prevalence 
estimates in Wuhan, China 
Niehus, R, De Salazar, P.M., Taylor, A. & Lipsitch, M | Lancet Infectious Diseases | 1 April 2020 | 
Article 
https://doi.org/10.1016/S1473-3099(20)30229-2 
Imported cases detected among travellers probably underestimates the true number. This would 
revise and reduce estimates of case-fatality. This model supports evidence that under detected 
cases of COVID-19 have probably spread in most locations around the world, with greatest risk in 
locations of low detection capacity and high connectively to the epicentre of the epidemic.  
Virological assessment of hospitalized patients with COVID-2019 
Wölfel, R. et al. | Nature | 1 April 2020 | Article 
https://doi.org/10.1038/s41586-020-2196-x 
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This study shows sites of COVID-19 viral shedding and timing versus symptoms. Infectious virus 
was readily isolated from throat- and lung derived samples, but not from stool samples, despite 
high virus RNA concentration. Blood and urine did not yield virus. Active virus replication in the 
upper respiratory tract was detected. Seroconversion mostly occurred during the second week of 
symptoms and coincided with a slow but steady decline in sputum viral load.  
COVID-19 pandemic in west Africa 
Martinez-Alvarez et al. | The Lancet Global Health | 1 April 2020 | Comment 
https://doi.org/10.1016/S2214-109X(20)30123-6 
No strong evidence exists supporting the claim that warmer temperatures will slow the spread of 
SARS-CoV-2. Early comparisons between the number of confirmed cases in the worst affected 
European countries and the west African countries with confirmed COVID-19 cases do not support 
the hypothesis that the virus will spread more slowly in countries with warmer climates. Includes a 
Figure showing how the pandemic initially evolved by total case numbers in west African countries 
compared with European countries and other African countries from the first and firth case 
diagnosed in the country. 
SARS-CoV-2 in wastewater: potential health risk, but also data source 
Lodder W. & de Roda Husman A.M. | The Lancet Gastroenterology & Hepatology | 1 April 2020 | 
Correspondence 
https://doi.org/10.1016/S2468-1253(20)30087-X 
This study detected SARS-CoV-2 in human wastewater in the Netherlands and could be the first 
report of SARS-CoV-2 in wastewater. Whether SARS-CoV-2 is viable under environmental 
conditions that could facilitate faecal-oral transmission is still not clear but some early reports 
suggest potential community spread in some geographic areas and where a newly developed case 
had not been exposed to anyone known to be infected with SARS-CoV-2 and had not travelled to 
countries in which the virus is circulating. However, it remains that enteric transmission of SARS-
CoV-2 is possible and exposure to SARS-CoV-2 in wastewater could pose a health risk. 
Wastewater surveillance of SARS-CoV-2 could be an early warning tool to indicate if the virus is 
circulating in the human population which would have implications particularly in areas with poor 
sanitation.  
Lessons from COVID-19: building more effective health services for a complex future 
Bloom, G. | IDS | 1 April 2020 | Opinion 
https://www.ids.ac.uk/opinions/lessons-from-covid-19-building-more-effective-health-services-for-
a-complex-future/ 
A greater willingness to act quickly and experiment at scale with approaches to organising services 
during the emergency response to COVID-19 will offer lessons that can be applied to creating 
more effective health systems going forward. Five aspects are particularly important - (1) the 
importance of government leadership; (2) the appropriate mix of good quality hospitals, primary 
healthcare services and public health; (3) measures that enable people to manage their own health 
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effectively; (4) the need for all parts of the health service to contribute to national goals; and (5) 
the potential contribution of new treatments, vaccines, diagnostic test and applications of 
communications technology. 
‘We have no choice.’ Pandemic forces polio eradication group to halt campaigns 
Roberts L | Science | 1 April 2020 | News 
https://www.sciencemag.org/news/2020/04/we-have-no-choice-pandemic-forces-polio-
eradication-group-halt-campaigns 
On 24 March, the Global Polio Eradication Initiative (GPEI) recommended suspending polio 
vaccine campaigns until at least the second half of this year to help stop the spread of COVID-19. 
Door to door delivery of oral polio vaccine would put both communities and health workers at risk 
of infection with SARS-CoV-2. This suspension will free up GPEI’s extensive resources, including 
surveillance systems and frontline health workers. On 26 March, WHO’s SAGE on Immunisation 
recommended all preventive mass vaccination campaigns for other diseases, including measles 
and yellow fever, be temporarily suspended. Routine immunisations at clinics and doctor’s offices 
should continue. 
Off-label use of medicines for COVID-19 
WHO | 31 March 2020 | Scientific brief 
https://apps.who.int/iris/bitstream/handle/10665/331640/WHO-2019-nCoV-Sci_Brief-Off-
label_use-2020.1-eng.pdf 
No pharmaceutical products have yet been shown to be safe and effective for the treatment of 
COVID-19, yet in many countries, doctors are giving COVID-19 patients medicines that have not 
been approved for this disease. Any “Off-label” use by doctors, outside of clinical trials, must be 
on a case-by-cases basis and must comply with national law.  Unnecessary stockpiling and the 
creation of shortages of approved medicines that are required to treat other diseases should be 
avoided. 
An investigation of transmission control measures during the first 50 days of the COVID-
19 epidemic in China 
Tian et al. | Science | 31 March 2020 | Report 
https://doi.org/10.1126/science.abb6105 
This analysis shows that non-pharmaceutical measures initiated during Chinese Spring Festival 
holiday, including the Wuhan city travel ban and the Level 1 national emergency response, were 
strongly associated with, though not necessarily the cause of, a delay in epidemic growth and a 
reduction in cases numbers during the first 50 days of the COVID-19 epidemic in China. The 
Wuhan shutdown was associated with the delayed arrival of COVID-19 in other cities by 2.91 days 
(95% C: 2.54-3.29), and fewer cases, on average, were seen in cities in the first week of outbreak 
that pre-emptively implemented control measures (13.0; 7.1-18.8) compared to cities that started 
control later (20.6; 14.5-26.8). Whether outcomes of control can be replicated outside of China 
remains to be determined. 
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Blocking information on COVID-19 can fuel the spread of misinformation 
Larson, H. | Nature | 30 March 2020 | World View 
https://www.nature.com/articles/d41586-020-00920-w 
Governments or their leaders repressing information in the hope of calming anxious publics, or 
deliberately releasing supposedly reassuring misinformation, risk undermining their own credibility 
and their abilities to help people respond to a health threat. This is about relationships between 
publics and politicians - a lack of trust in the motives of governing powers and fears among leaders 
that the truth would spark public disorder and dissent. Examples are provided within the COVID-
19 context.  
1. Tracking COVID-19 cases 
Global 
WHO COVID-19 daily situation reports 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 
An interactive web-based dashboard to track COVID-19 in real time 
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467
b48e9ecf6 
Live data tracker: sex-disaggregated COVID-19 data from the 25 most-affected countries 
http://globalhealth5050.org/covid19 
Africa 
Coronavirus in Africa Tracker: How many covid-19 cases & where? 
https://africanarguments.org/2020/03/23/coronavirus-in-africa-tracker-how-many-cases-and-
where-latest/ 
UK 
COVID-19: PHE track coronavirus cases in the UK 
https://www.gov.uk/government/publications/covid-19-track-coronavirus-cases 
UK case tracing infographic 
https://www.arcgis.com/apps/opsdashboard/index.html#/f94c3c90da5b4e9f9a0b19484dd4bb14 
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2. Online course 
Responding to COVID-19: Real-time training for the coronavirus disease outbreak 
WHO | Available now | multiple self-paced courses 
https://openwho.org/channels/covid-19 
Note that courses are available in English and other languages including French, Portuguese 
and Spanish. 
COVID-19: Tackling the Novel Coronavirus 
LSHTM | FutureLearn course | Starts 23 March 2020 | 3 weeks | 4 hours weekly study | Free 
https://www.futurelearn.com/courses/covid19-novel-coronavirus 
A reminder that this course is currently running. On this course you will learn what is known 
about the outbreak of COVID-19 (week 1); what the practical implications for responding to 
COVID-19 are (week 2); and what we need to find out about COVID-19 (week 3). 
3. Resource Hubs 
COVID-19: Resources and research on epidemics and pandemics 
https://steps-centre.org/covid-19-coronavirus-resources-research-epidemics-pandemics/ 
Stop TB Partnership TB and COVID-19 
http://www.stoptb.org/covid19.asp 
EPI-WIN: WHO information network for epidemics: COVID-19 public health emergency 
https://www.who.int/teams/risk-communication 
COVID-19: Research ethics 
https://ethicsresource.ringsgenderresearch.org/covid-19-resources/ 
LSTM: COVID-19 
https://www.lstmed.ac.uk/covid-19 
LSHTM: COVID-19 
https://www.lshtm.ac.uk/research/research-action/covid-19 
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International Disability Alliance: COVID 19 and the disability movement 
http://www.internationaldisabilityalliance.org/content/covid-19-and-disability-movement 
Africa Centres for Disease Control and Prevention (Africa CDC) 
https://africacdc.org/covid-19/ 
UNICEF: Latest news and updates on coronavirus disease 2019 (COVID-19) 
https://www.unicef.org/coronavirus/covid-19 
Coronavirus: the science explained 
https://coronavirusexplained.ukri.org/en/ 
Social Science in Humanitarian Action: Updates on the novel COVID-19 outbreak 
https://www.socialscienceinaction.org/update-novel-covid-19-outbreak/ 
Special Collection: Coronavirus (COVID-19): evidence relevant to critical care 
https://www.cochrane.org/news/special-collection-coronavirus-covid-19-evidence-relevant-
critical-care 
NICE UK: Rapid guidelines and evidence reviews  
https://www.nice.org.uk/covid-19 
Imperial College London MRC Centre for Global Infectious Disease Analysis COVID-19 
reports 
https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus/ 
Global research on COVID-19 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-
coronavirus-2019-ncov 
WHO R&D Blueprint 
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/ 
WHO: Coronavirus disease (COVID-19) outbreak resources 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019 
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Latest information and advice from the UK Government 
https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public 
CDC COVID-19 Resources 
https://www.cdc.gov/coronavirus/2019-ncov/index.htmlThe Global Health Network Coronavirus 
outbreak knowledge hub 
The Lancet COVID-19 Resource Centre 
https://www.thelancet.com/coronavirus 
Elsevier’s Novel Coronavirus Information Center 
https://www.elsevier.com/connect/coronavirus-information-center 
Cell Press Coronavirus Resource Hub 
https://www.cell.com/2019-nCOV 
Cochrane Special Collections - COVID-19: infection control and prevention measures 
https://www.cochranelibrary.com/collections/doi/SC000040/full 
The BMJ Coronavirus (covid-19): Latest news and resources 
https://www.bmj.com/coronavirus?int_source=wisepops&int_medium=wisepops&int_campaign=
DAA_CoronaVirus_Jan24 
Johns Hopkins Coronavirus Resource Centre 
https://coronavirus.jhu.edu 
Global Partnership for Sustainable Development – COVID-19 resources 
http://www.data4sdgs.org/resources/covid-19-resources 
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About this report 
This daily COVID-19 health evidence summary is based on 2 to 2.5 hours of desk-based research. K4D services 
are provided by a consortium of leading organisations working in international development, led by the Institute of 
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International Development Department (IDD) and the University of Manchester Humanitarian and Conflict 
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This evidence summary was prepared for the UK Government’s Department for International 
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